Navigation Links
TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
Date:11/12/2008

ations management, healthcare utilization and organizational planning at Bayer Corporation and Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Ms. Graham holds a B.A. in biology from the University of Delaware and an M.B.A. from the University of Connecticut.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company contact: Investor contact:

Paul Schneider Rhonda Chiger

TorreyPines Therapeutics, Inc. Rx Communications Group

858-623-5665
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
2. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
5. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
6. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
11. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) ... market segments, including the molecular diagnostics industry. BCC Research reveals in its new report ... tests, lower test costs, and a growing need for better diagnostics as part of ...
(Date:7/1/2015)... 2015 Isagenix International, a leading global health ... three Silver, and three Bronze Stevie® Awards at the ... Chicago this month.The American Business ... program in the U.S. "Winning is ... developing leaders, cultivating talent, creating a unified team, and ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection ... an operator control device that will increase healthcare worker safety and reduce financial ...
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... Corporation, a company enabling a new generation of molecular ... Mo lecule A rray (SiMoA ™ ) ... measure biomarkers of inflammation from patients with Crohn,s disease. ... was possible using Quanterix,s high sensitivity digital ELISA, allowed ...
... small package. For instance, these tiny cylinders of carbon ... than a metal conductor of the same size. It,s ... future nanoscale electronics. Butnot so fast. Recent tests ... suggest device reliability is a major issue. Copper ...
... CBI is pleased to announce the full agenda for ... being held September 20-22, 2011 in Philadelphia, PA. The ... from Celgene, Covidien, FDA, Forest, Ironwood Pharmaceuticals, Merck, NIH, ... Attendees have the opportunity to customize their congress experience ...
Cached Biology Technology:Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohn's Disease 2NIST uncovers reliability issues for carbon nanotubes in future electronics 2FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress 2
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... implant such as a new hip or pacemaker with nanosized ... the University of Gothenburg, Sweden, can now explain why: they ... the International Journal of Nanomedicine . "Activation of ... common reasons for an implant being rejected," explains Professor Hans ...
... of ageing on the immune system received a boost ... (BBSRC) announced investment in a new 3.6 million research ... from the Babraham Institute with partners from the University ... The team hopes to illuminate a fundamental but little ...
... Livermore National Laboratory Geochemist Tom Guilderson has been ... prestigious Ernest Orlando Lawrence Award, Energy Secretary Steven ... for ground-breaking radiocarbon measurements of corals, advancements in ... processes revealing past climate variability, and the explanation ...
Cached Biology News:Cobblestones fool innate immunity 2New research aims to shed light on how aging affects immunity 2New research aims to shed light on how aging affects immunity 3Geochemist Tom Guilderson wins E.O. Lawrence Award for radiocarbon work 2
FRACTALKINE [Human] (Recombinant)...
... Operating head automatically rises at the end of determination; triple-point calibration verification; refrigerator eliminates need for pumps ... ... ... ...
... System with the xPONENT Software Interface ... multi-analyte assays using Upstate's Beadlyte® reagents. ... user friendly xPONENT software developed by ... templates for commercial or home-made multiplex ...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
Biology Products: